<DOC>
	<DOCNO>NCT00701363</DOCNO>
	<brief_summary>The purpose study assess efficacy extend injection interval schedule lanreotide Autogel 120 mg acromegalic subject biochemically control long term treatment octreotide LAR 10 20 mg</brief_summary>
	<brief_title>Study Assess Efficacy Extended Injection Interval Schedule Lanreotide Autogel Acromegalic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>The subject give write informed consent prior studyrelated procedure The subject male female 18 year age The subject must documentation support diagnosis acromegaly , base elevate IGF1 and/or GH level The subject receive octreotide LAR ( 10 20 mg ) treatment least six month biochemically control . Control define normal ( age sex adjust ) IGF 1 level two consecutive measurement ( least two month apart ) precede study entry If subject receive dopamine agonist therapy , treatment stable least four month , change dopamineagonist medication expect entire study period The subject receive radiation therapy pituitary gland study entry The subject history hypersensitivity lanreotide drug similar chemical structure The subject receive growth hormone receptor antagonist ( pegvisomant ) therapy within three month study entry The subject undergone treatment investigational drug 30 day study entry schedule receive investigational drug , lanreotide 120 mg , course study The subject receive unlicensed drug within 30 day prior baseline visit schedule receive unlicensed drug course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>